Hypermethylation of VTRNA2-1 Promoter in HCC Outcome

Hepatocellular Carcinoma Resectable Clinical Trial

Official title:

Differential Hypermethylation Status of the VTRNA2-1 Promoter in Hepatocellular Carcinoma as an Independent Factor After Partial Hepatectomy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04177316
• Other study ID #: 201801969B0
• Status: Completed
• Start date: December 1, 2018
• Est. completion date: November 15, 2019

Study information

• Verified date: November 2019
• Source: Chang Gung Memorial Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.

Description:

This study was approved by the Institute Review Board (IRB) of Chang Gung Memorial Hospital, Linkou Branch (IRB 201801969B0). The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled, all patients had curative hepatectomy and those with different cancers were excluded. HCC tumor tissue and normal tissue, 3 cm from the tumor margin, were stored immediately in a -80 degree freezer at the Central Biobank of Chang Gung Memorial Hospital. The personal information was protected with decoding and registered with number.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. completion date: November 15, 2019
• Est. primary completion date: November 15, 2019
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

subjects with pathologic diagnosis of hepatocellular carcinoma curative partial hepatectomies

Exclusion Criteria:

history of different malignant disease. subjects cannot be treated with curative surgery.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Hepatocellular Carcinoma Resectable

Locations

Country	Name	City	State
Taiwan	Ming-Chin Yu	Taoyuan

Sponsors (1)

Lead Sponsor	Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	disease free survival (DFS)	The length of time from curative hepatectomies treatment and recurrence or mortality	a month
Secondary	Overall survival	The length of time from hepatectomies treatment for HCC and still alive.	a month